E
Edmond J. LaVoie
Researcher at Rutgers University
Publications - 182
Citations - 8160
Edmond J. LaVoie is an academic researcher from Rutgers University. The author has contributed to research in topics: Topoisomerase & Cytotoxicity. The author has an hindex of 42, co-authored 178 publications receiving 7619 citations. Previous affiliations of Edmond J. LaVoie include San Antonio River Authority & National Pingtung University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Bioisosterism: A Rational Approach in Drug Design.
George Patani,Edmond J. LaVoie +1 more
TL;DR: This topic has been reviewed in previous years and the objective of this review is to provide an overview of bioisosteres that incorporates sufficient detail to enable the reader to understand the concepts being delineated.
Journal ArticleDOI
Antioxidative Phenolic Compounds from Sage (Salvia officinalis)
Mingfu Wang,Jiangang Li,Meera Rangarajan,Yu Shao,Edmond J. LaVoie,Tzou-Chi Huang,Chi-Tang Ho +6 more
TL;DR: In this article, 10 phenolic compounds were isolated from a butanol fraction of sage extracts and their structures were determined by spectral methods (NMR, MS, IR). Among them, a novel compound, 4-hydroxyacetophenone-4-O-β-d-apiofuranosyl-(1→6)-O- β-dglucopyranoside, was identified.
Journal ArticleDOI
Substituted 2,5'-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity.
TL;DR: Several 2'-aryl-5-substituted-2,5'bi-1H-benzimidazole derivatives were synthesized and evaluated as topoisomerase I poisons and for their cytotoxicity toward the human lymphoblast cell line RPMI 8402.
Journal ArticleDOI
Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation.
TL;DR: It is demonstrated that thiol alkylation of TOP2 can also produce TOP2-mediated DNA damage, suggesting the possibility that cellular DNA damage could occur indirectly through thiolation of a nuclear protein, TOP2.
Journal Article
Identification of Topoisomerase I as the Cytotoxic Target of the Protoberberine Alkaloid Coralyne
Barbara Gatto,Marilyn M. Sanders,Chiang Yu,Hong Yan Wu,Makhey Darshan B,Edmond J. LaVoie,Leroy-Fong Liu +6 more
TL;DR: It seems possible to develop coralyne and nitidine derivatives as new topo I-targeted therapeutics to overcome aspects of camptothecin-related resistance.